Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1957 1
1966 4
1967 2
1968 1
1969 5
1970 1
1971 3
1972 2
1973 4
1974 3
1975 7
1976 4
1977 5
1978 6
1979 9
1980 6
1981 8
1982 2
1983 5
1984 5
1985 2
1986 4
1989 3
1990 8
1991 7
1992 8
1993 3
1994 7
1995 4
1996 7
1997 8
1998 5
1999 15
2000 15
2001 11
2002 13
2003 5
2004 6
2005 10
2006 11
2007 11
2008 10
2009 18
2010 26
2011 16
2012 34
2013 34
2014 32
2015 25
2016 18
2017 21
2018 27
2019 7
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

461 results
Results by year
Filters applied: . Clear all
Page 1
Mycosis Fungoides and Sezary Syndrome.
Foss FM and Girardi M. Hematol Oncol Clin North Am 2017 - Review. PMID 28340880
Mycosis fungoides and the Sezary syndrome (SS) are rare lymphomas of CD4(+) helper T cells. There is stagewise progression from patch/plaques to thicker tumor lesions/diffuse erythroderma. ...
Mycosis fungoides and the Sezary syndrome (SS) are rare lymphomas of CD4(+) helper T cells. There is stagewise progression fro
Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B, et al. Curr Opin Oncol 2016 - Review. PMID 26632770
PURPOSE OF REVIEW: Mycosis fungoides and Sézary syndrome arise from malignant T cells that reside in skin, and subsequently are capable of circulating between skin, lymph nodes, and blood. ...RECENT FINDINGS: Recent studies have discovered that malignant T cells in Sézary syndrome are of the central memory T-cell subset, whereas those in mycosis fungoides are nonrecirculating skin-resident effector memory T cells, and have shown a protumorigenic role of mast cells and macrophages in CTCL. ...
PURPOSE OF REVIEW: Mycosis fungoides and Sézary syndrome arise from malignant T cells that reside in skin, and subsequently ar …
Mycosis fungoides progression could be regulated by microRNAs.
Manso R, et al. PLoS One 2018. PMID 29894486 Free PMC article.
Differentiating early mycosis fungoides (MF) from inflammatory dermatitis is a challenge. We compare the differential expression profile of early-stage MF samples and benign inflammatory dermatoses using microRNA (miRNA) arrays. 114 miRNAs were found to be dysregulated between these entities. ...
Differentiating early mycosis fungoides (MF) from inflammatory dermatitis is a challenge. We compare the differential expressi …
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ, et al. Eur J Cancer 2018 - Review. PMID 29477101 Free article.
Our current mycosis fungoides (MF) and Sézary Syndrome (SS) staging system includes blood-classification from B0-B2 for patch/plaque/tumour or erythroderma based on manual Sézary counts but results from our EORTC survey confirm these are rarely performed in patch/plaque/tumour MF, and there is a trend towards using flow cytometry to measure blood-class. ...
Our current mycosis fungoides (MF) and Sézary Syndrome (SS) staging system includes blood-classification from B0-B2 for patch/ …
The biomarker landscape in mycosis fungoides and Sézary syndrome.
Dulmage B, et al. Exp Dermatol 2017 - Review. PMID 27897325 Free PMC article.
Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. ...
Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and
Mycosis fungoides with spongiosis: A potential diagnostic pitfall.
Shamim H, et al. J Cutan Pathol 2019. PMID 30989664
BACKGROUND: Mycosis fungoides (MF) is characterized by epidermotropic atypical lymphocytes in the absence of spongiosis. However, we describe an unusual presentation of MF with spongiosis, mimicking benign inflammatory dermatoses and highlight the importance of pathologic interpretation for diagnostic confirmation. ...
BACKGROUND: Mycosis fungoides (MF) is characterized by epidermotropic atypical lymphocytes in the absence of spongiosis. Howev …
Expression of SOX18 in Mycosis Fungoides.
Jankowska-Konsur A, et al. Acta Derm Venereol 2017. PMID 27230943 Free article.
So far, no studies on the role of SOX18 expression in mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, have been performed. ...
So far, no studies on the role of SOX18 expression in mycosis fungoides (MF), the most common primary cutaneous T-cell lymphom …
Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A, et al. Anticancer Res 2016. PMID 27630298
BACKGROUND/AIM: Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL) characterized by malignant proliferation of mature T lymphocytes and primary skin involvement. ...
BACKGROUND/AIM: Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL) characterized by malignant …
CD8(+) mycosis fungoides: A low-grade lymphoproliferative disorder.
Martinez-Escala ME, et al. J Am Acad Dermatol 2017. PMID 28676328
BACKGROUND: The prognosis of the CD8(+) subtype of mycosis fungoides (MF) is controversial. Although most authors believe that determining the presence of this cell surface antigen has no prognostic value, others have observed a more indolent course for CD8(+) MF compared with CD4(+) MF. ...
BACKGROUND: The prognosis of the CD8(+) subtype of mycosis fungoides (MF) is controversial. Although most authors believe that …
461 results
Jump to page
Feedback